In summary, our findings demonstrate that FADS1 inhibition effectively curtails renal cancer cell proliferation in vitro as well as tumor formation in vivo, primarily through the activation of the ATF3 axis-mediated ER stress. The gene discussed is ATF3; the disease is renal carcinoma.